James C. Stolzenbach
AbbVie (United States)(US)
Publications by Year
Research Areas
Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, Pharmacogenetics and Drug Metabolism, Analytical Methods in Pharmaceuticals
Most-Cited Works
- → Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis(2003)953 cited
- → Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: A phase 3 study(2008)90 cited
- → Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: A phase 3, randomized, controlled study(2008)81 cited
- → Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy(2014)66 cited
- → Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia(2008)66 cited
- → Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia(2008)50 cited
- → Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus(2010)39 cited
- → Determination of protein binding byin vitro charcoal adsorption(1995)38 cited
- → Efficacy and Safety of Rosuvastatin and Fenofibric Acid Combination Therapy versus Simvastatin Monotherapy in Patients with Hypercholesterolemia and Hypertriglyceridemia(2010)37 cited
- → Evaluation of a New Formulation of Fenofibric Acid, ABT-335, Co-Administered with Statins(2008)35 cited